
CI-966 hydrochloride
CAS No. 110283-66-4
CI-966 hydrochloride( CI966 )
Catalog No. M10394 CAS No. 110283-66-4
CI-966 is a potent, selective inhibitor of the GABA transporter GAT-1 with IC50 of 0.26 and 1.2 uM for human and rat GAT-1, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 138 | Get Quote |
![]() ![]() |
50MG | 1782 | Get Quote |
![]() ![]() |
100MG | 2250 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameCI-966 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionCI-966 is a potent, selective inhibitor of the GABA transporter GAT-1 with IC50 of 0.26 and 1.2 uM for human and rat GAT-1, respectively.
-
DescriptionCI-966 is a potent, selective inhibitor of the GABA transporter GAT-1 with IC50 of 0.26 and 1.2 uM for human and rat GAT-1, respectively; displays >200-fold selectivity over GAT-2 and GAT-3; shows anticonvulsive and neuroprotective activity in vivo.Epilepsy Phase 1 Discontinued.
-
In VitroCI-966 hydrochloride functions by selectively inhibiting GABA reuptake in neurons and glial cells.
-
In VivoCI-966 hydrochloride produces intermediate levels of Pentylenetetrazol (PTZ)-lever responding when administered to PTZ-trained rats.CI-966 hydrochloride enhances gamma-aminobutyric acid action in CA1 pyramidal layer in situ. CI-966 hydrochloride is administered systemically by i.p. injection (5 mg/kg) in Sprague-Dawley rats under urethane anaesthesia. Twenty to thirty minutes after injection there is a highly variable, but overall significant, enhancement of the inhibition of hippocampal population spikes by GABA applied by microiontophoresis in the CA1 region. CI-966 hydrochloride exhibits anticonvulsant properties in various animal models. Oral absorption of CI-966 hydrochloride in dogs given 1.39 mg/kg is rapid with a tmax of 0.7 hr.In rats given 5 mg/kg oral, a mean tmax of 4.0 hr is observed. Following i.v. administration of the same respective doses, elimination t1/2 in dogs and rats averages 1.2 and 4.5 hr. Absolute oral bioavailability of CI-966 hydrochloride is 100% in both species. Animal Model:Eight male Sprague-Dawley ratsDosage:0.3-30 mg/kg Administration:Injection IP in a volume of 1 mL/kg Result:Dose dependent decreases in rates of responding occurred following CI-966 administration.
-
SynonymsCI966
-
PathwayMembrane Transporter/Ion Channel
-
TargetGAT
-
RecptorGAT
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number110283-66-4
-
Formula Weight509.873
-
Molecular FormulaC23H22ClF6NO3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (98.06 mM)
-
SMILESC1CN(CC(=C1)C(=O)O)CCOC(C2=CC=C(C=C2)C(F)(F)F)C3=CC=C(C=C3)C(F)(F)F.Cl
-
Chemical Name1-[2-[bis[4-(Trifluoromethyl)phenyl]methoxy]ethyl]-1,2,5,6-tetrahydropyridine-3-carboxylic acid hydrochloride
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ebert U, et al. Can J Physiol Pharmacol. 1990 Sep;68(9):1194-9.
2. Radulovic LL, et al. Pharm Res. 1993 Oct;10(10):1442-5.
3. Phillis JW. Gen Pharmacol. 1995 Sep;26(5):1061-4.
molnova catalog



related products
-
4-Aminobutyric acid
The most common inhibitory neurotransmitter in the central nervous system.
-
Oxiracetam
Oxiracetam, a cyclic derivative of gamma-aminobutyric acid (GABA), is used as a nootropic drug to improve memory and learning.
-
Vigabatrin Hydrochlo...
Vigabatrin Hcl(γ-Vinyl-GABA; Sabril) is a structural analog of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) that irreversibly inhibits the catabolism of GABA by GABA transaminase.